Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer

Cancer Science

Volumn 99, Issue 3, 2008, Pages 582-589

  Jin, Xianqing ^a   Wang, Ziming ^b   Qiu, Lin ^a   Zhang, Dianliang ^c   Guo, Zhenhua ^a   Gao, Zongwei ^d   Deng, Chun ^a   Wang, Fuling ^c   Wang, Shan ^a   Guo, Chunbao ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

^d Linyi Municipal Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELA;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; EARLY CANCER; FEMALE; FISHER EXACT TEST; FOLLOW UP; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; LOG RANK TEST; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SMOKING; SURVIVAL RATE; UNIVARIATE ANALYSIS;

EID: 38949094884     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00713.x     Document Type: Article

References (39)

1. Hu Y, McDermott MP, Ahrendt SA. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 2005; 11 (7): 2502-9.
2. Kim JS, Kim JW, Han J, Shim YM, Park J, Kim DH. Cohypermethylation of p16 and FHIT promoters as a prognostic factor of recurrence in surgically resected stage I non-small cell lung cancer. Cancer Res 2006; 66 (8): 4049-54.
3. Lu C, Soria JC, Tang X et al. Prognostic factors in resected stage I non-small-cell lung cancer: A multivariate analysis of six molecular markers. J Clin Oncol 2004; 22 (22): 4575-83.
4. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: A review. Clin Cancer Res 2005; 11 (11): 3974-86.
5. Esposito V, Baldi A, Tonini G et al. Analysis of cell cycle regulator proteins in non-small cell lung cancer. J Clin Pathol 2004; 57 (1): 58-63.
6. Le QT, Chen E, Salim A et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 2006; 12 (5): 1507-14.
7. Birim O, Kappetein AP, van Klaveren RJ, Bogers AJ. Prognostic factors in non-small cell lung cancer surgery. Eur J Surg Oncol 2006; 32 (1): 12-23.
8. Kapahi P, Takahashi T, Natoli G et al. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J Biol Chem 2000; 275 (46): 36062-6.
9. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20 (31): 4188-97.
10. Ross JS, Kallakury BV, Sheehan CE et al. Expression of nuclear factor-kappa B and I kappa B alpha proteins in prostatic adenocarcinomas: Correlation of nuclear factor-kappa B immunoreactivity with disease recurrence. Clin Cancer Res 2004; 10 (7): 2466-72.
11. Sasaki N, Morisaki T, Hashizume K et al. Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 2001; 7 (12): 4136-42.
12. El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH. Potentiation of the effect of erlotinib by genistein in pancreatic cancer: The role Akt nuclear factor-{kappa}B. Cancer Res 2006; 66 (21): 10553-9.
13. Huber MA, Azoitei N, Baumann B et al. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004; 114 (4): 569-81.
14. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 2007; 13 (4): 1076-82.
15. Zhang Z, Ma J, Li N, Sun N, Wang C. Expression of nuclear factor-kappaB and its clinical significance in nonsmall-cell lung cancer. Ann Thorac Surg 2006; 82 (1): 243-8.
16. Tang X, Liu D, Shishodia S, Ozburn N et al. Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 2006; 107 (11): 2637-46.
17. Guo CB, Wang S, Deng C, Zhang DL, Wang FL, Jin XQ. Relationship between matrix metalloproteinase 2 and lung cancer progression. Mol Diagn Ther 2007; 11 (3): 183-92.
18. Lee BL, Lee HS, Jung J et al. Nuclear factor-kappaB activation correlates with better prognosis and Akt activation in human gastric cancer. Clin Cancer Res 2005; 11 (7): 2518-25.
19. Yang J, Richmond A. Constitutive IkappaB kinase activity correlates with nuclear factor-kappaB activation in human melanoma cells. Cancer Res 2001; 61 (22): 8150-7.
20. Stathopoulos GT, Zhu Z, Everhart MB et al. Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 2006; 34 (2): 142-50.
21. Bayon Y, Ortiz MA, Lopez-Hernandez FJ et al. Inhibition of IkappaB kinase by a new class of retinoid-related anticancer agents that induce apoptosis. Mol Cell Biol 2003; 23 (3): 1061-74.
22. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel retinoid-related molecule requires nuclear factor-kappaB activation. Cancer Res 2005; 65 (11): 4909-17.
23. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-kappaB kinase and aberrant nuclear factor-kappaB activation by serum factor (s) in head and neck squamous carcinoma cells. Cancer Res 2006; 66 (13): 6722-31.
24. Dolcet X, Llobet D, Encinas M et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 2006; 281 (31): 22118-30.
25. Tergaonkar V, Bottero V, Ikawa M, Li Q, Verma IM. IkappaB kinase-independent IkappaBalpha degradation pathway: Functional NF-kappaB activity and implications for cancer therapy. Mol Cell Biol 2003; 23 (22): 8070-83.
26. Li Z, Niu J, Uwagawa T, Peng B, Chiao PJ. Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response. J Biol Chem 2005; 280 (17): 16843-50.
27. Charalambous MP, Maihofner C, Bhambra U, Lightfoot T, Gooderham NJ; Colorectal Cancer Study Group. Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells. Br J Cancer 2003; 88 (10): 1598-604.
28. Baeuerle PA, Baltimore DI kappa B. a specific inhibitor of the NF-kappa B transcription factor. Science 1988; 242 (4878): 540-6.
29. Imbert V, Rupec RA, Livolsi A et al. Tyrosine phosphorylation of I kappa B-alpha activates NF-kappa B without proteolytic degradation of I kappa B-alpha. Cell 1996; 86 (5): 787-98.
30. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature 1997; 388 (6642): 548-54.
31. O'Connor S, Shumway S, Miyamoto S. Inhibition of IkappaBalpha nuclear export as an approach to abrogate nuclear factor-kappaB-dependent cancer cell survival. Mol Cancer Res 2005; 3 (1): 42-9.
32. Mabuchi S, Ohmichi M, Nishio Y et al. Inhibition of NFkappaB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004; 279 (22): 23477-85.
33. Babbar N, Hacker A, Huang Y, Casero RA Jr. Tumor necrosis factor alpha induces spermidine/spermine N1-acetyltransferase through nuclear factor kappaB in non-small cell lung cancer cells. J Biol Chem 2006; 281 (34): 24182-92.
34. Mabuchi S, Ohmichi M, Nishio Y et al. Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004; 10 (22): 7645-54.
35. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling. balancing life and death - a new approach to cancer therapy. J Clin Invest 2005; 115 (10): 2625-32.
36. Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol 2005; 25 (6): 541-50.
37. Taillade L, Penault-Llorca F, Boulet T et al. Immunohistochemichal expression of biomarkers: A comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 2007; 18 (6): 1043-50.
38. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9 (3): 189-98.
39. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: Molecular biology of lung cancer: Clinical implications. Thorax 2003; 58 (10): 892-900.